Table 3.
Classification
|
Drugs
|
|
Antiviral agents | Favipiravir, molnupiravir, paxlovid, remdesivir | |
Immunomodulatory agents | ||
JAK inhibitors | Baricitinib, ruxolitinib, tofacitinib | |
Monoclonal antibodies to IL-6 | Sarilumab, tocilizumab | |
Corticosteroids | Cortisol, dexamethasone, methylprednisolone | |
Monoclonal antibodies to SARS-CoV-2 | Bamlanivimab, casirivimab, etesevimab, imdevimab, sotrovimab | |
COVID-19 vaccines | ||
mRNA | BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna] | |
Adenovirus vector | ChAdOx1-S [AstraZeneca, Oxford]; Ad26.COV2.S [Johnson and Johnson, Janssen], Sputnik-V-Gam - COVID Vac Ad5+Ad26 [Gamleaya] | |
Recombinant nanoparticles | NVX-CoV2373 [Novavax] | |
Miscellaneous agents | Azithromycin, chloroquine, dexamethasone, fluvoxamine, hydroxychloroquine, ivermectin |
COVID-19: Coronavirus disease 19; IL-6: Interleukin-6; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.